Denileukin diftitox

Source: Wikipedia, the free encyclopedia.
Denileukin diftitox
Clinical data
Trade namesOntak
AHFS/Drugs.comMonograph
MedlinePlusa611024
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life70-80 min
Identifiers
  • Diphtheria toxin-Interleukin-2 fusion protein
CAS Number
IUPHAR/BPS
DrugBank
ChemSpider
  • none
UNII
ChEMBL
Chemical and physical data
FormulaC2560H4042N678O799S17
Molar mass57647.46 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Denileukin diftitox (trade name Ontak) was an antineoplastic agent, an engineered protein combining

interleukin-2 receptors[1] and introduce the diphtheria toxin into cells that express those receptors, killing the cells. In some leukemias and lymphomas
, malignant cells express these receptors, so denileukin diftitox can target these.

In 1999, Ontak was approved by the

There is some evidence tying it to vision loss, and in 2006 the FDA added a

black box warning to the drug's label.[3]

In 2014, marketing of Ontak was discontinued in the US.[4]

References

  1. S2CID 9028829
    .
  2. .
  3. .
  4. ^ "FDA Drug Shortages". U.S. Food and Drug Administration. 31 January 2014. Retrieved 3 July 2017.

External links